Novartis Ag

Dimitris Papoutsakis

Stephen Paul Collingwood

Piotr Henryk Karpinski

Urs Baettig

Simon James Watson

Brian Cox

Neil John Press

Sudhakar Devidasrao Garad

Hyungchul Kim

Murat Acemoglu

Paul Allen Sutton

Yugang Liu

Frank Stowasser

Stéphanie Monnier

Joel Slade

Joginder S Bajwa

Elias Ndzie

Elizabeth Roddy

The invention relates to a new crystalline form of the acetate salt of which may be used, for example, for prevention or treatment of transplant rejection.

[object Object]

This invention relates to a novel crystalline form (Form A) of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this crystalline form, to processes for forming it and to its use in medical treatment.

Polymorphic form of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic

Compounds of Formula (I); in salt or zwitterionic form wherein R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described. 

Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists

Polymorphic forms of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide free base and salts thereof are prepared by various processes.

Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide

Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists

Growing community of inventors

Acton, MA, United States of America

Dimitris Papoutsakis